Roth Capital Has Pessimistic Outlook of CELZ Q2 Earnings

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) – Stock analysts at Roth Capital decreased their Q2 2025 EPS estimates for shares of Creative Medical Technology in a report released on Wednesday, June 4th. Roth Capital analyst J. Aschoff now anticipates that the company will earn ($0.63) per share for the quarter, down from their prior forecast of ($0.40). The consensus estimate for Creative Medical Technology’s current full-year earnings is ($3.19) per share. Roth Capital also issued estimates for Creative Medical Technology’s Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.93) EPS, FY2025 earnings at ($3.00) EPS, FY2026 earnings at ($2.85) EPS, FY2027 earnings at $2.19 EPS, FY2028 earnings at $4.37 EPS and FY2029 earnings at $5.76 EPS.

Creative Medical Technology Price Performance

Shares of NASDAQ:CELZ opened at $2.42 on Monday. The stock has a market cap of $6.26 million, a P/E ratio of -0.64 and a beta of 1.98. The firm has a fifty day moving average price of $2.06 and a 200 day moving average price of $2.74. Creative Medical Technology has a 1-year low of $1.69 and a 1-year high of $6.90.

Creative Medical Technology (NASDAQ:CELZ) last issued its quarterly earnings results on Friday, May 9th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.31). The company had revenue of $0.00 million for the quarter.

Institutional Trading of Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Armistice Capital LLC bought a new position in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 148,000 shares of the company’s stock, valued at approximately $321,000. Armistice Capital LLC owned 3.38% of Creative Medical Technology as of its most recent filing with the Securities and Exchange Commission. 1.42% of the stock is owned by institutional investors.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.